Prevention of Ebola virus disease through vaccination: where we are in 2018.
作者信息
Lévy Yves, Lane Clifford, Piot Peter, Beavogui Abdul Habib, Kieh Mark, Leigh Bailah, Doumbia Seydou, D'Ortenzio Eric, Lévy-Marchal Claire, Pierson Jerome, Watson-Jones Deborah, Nguyen Vinh-Kim, Larson Heidi, Lysander Julia, Lacabaratz Christine, Thiebaut Rodolphe, Augier Augustin, Ishola David, Kennedy Stephen, Chêne Geneviève, Greenwood Brian, Neaton James, Yazdanpanah Yazdan
机构信息
French Institute for Health and Medical Research (Inserm), Paris, France.
National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
出版信息
Lancet. 2018 Sep 1;392(10149):787-790. doi: 10.1016/S0140-6736(18)31710-0. Epub 2018 Aug 10.
Abstract
摘要
相似文献
1
Prevention of Ebola virus disease through vaccination: where we are in 2018.通过接种疫苗预防埃博拉病毒病：2018年我们所处的状况
Lancet. 2018 Sep 1;392(10149):787-790. doi: 10.1016/S0140-6736(18)31710-0. Epub 2018 Aug 10.
2
Ebola vaccines in clinical trial: The promising candidates.处于临床试验阶段的埃博拉疫苗：前景光明的候选疫苗。
Hum Vaccin Immunother. 2017 Jan 2;13(1):153-168. doi: 10.1080/21645515.2016.1225637. Epub 2016 Oct 20.
3
Getting the most from the Ebola vaccine success.从埃博拉疫苗的成功中获取最大收益。
Vaccine. 2015 Dec 16;33(51):7141. doi: 10.1016/j.vaccine.2015.10.130. Epub 2015 Nov 10.
4
A vaccine against Ebola: Problems and opportunities.一种抗埃博拉疫苗：问题与机遇。
Hum Vaccin Immunother. 2015;11(5):1258-60. doi: 10.1080/21645515.2015.1021528.
5
A DNA vaccine for the prevention of Ebola virus infection.一种用于预防埃博拉病毒感染的DNA疫苗。
Curr Opin Mol Ther. 2008 Jun;10(3):285-93.
6
Immunology of protection from Ebola virus infection.埃博拉病毒感染的免疫保护。
Sci Transl Med. 2015 May 6;7(286):286ps11. doi: 10.1126/scitranslmed.aaa8202.
7
Ebola vaccine is safe and immunogenic, results show.结果显示，埃博拉疫苗安全且具有免疫原性。
BMJ. 2015 Jan 29;350:h524. doi: 10.1136/bmj.h524.
8
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.在欧洲（EBOVAC2）进行的一项成人两剂次异源 Ad26.ZEBOV 和 MVA-BN-Filo 埃博拉疫苗方案的安全性和免疫原性：一项随机、观察者盲、参与者盲、安慰剂对照、2 期临床试验。
Lancet Infect Dis. 2021 Apr;21(4):493-506. doi: 10.1016/S1473-3099(20)30476-X. Epub 2020 Nov 17.
9
Ebola vaccine trials: a race against the clock.埃博拉疫苗试验：与时间赛跑。
Lancet Infect Dis. 2015 Jun;15(6):624-6. doi: 10.1016/S1473-3099(15)70159-3. Epub 2015 Apr 14.
10
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.在非洲儿童中使用黑猩猩腺病毒载体埃博拉疫苗的安全性、反应原性和免疫原性：一项随机、观察者盲法、安慰剂对照、2 期临床试验。
Lancet Infect Dis. 2020 Jun;20(6):719-730. doi: 10.1016/S1473-3099(20)30019-0. Epub 2020 Mar 19.
引用本文的文献
1
Healthcare Providers' and Frontline Workers' Experiences of an Ebola Vaccine Trial in the Boende Health District of the Democratic Republic of the Congo.卫生保健提供者和一线工作者在刚果民主共和国博恩代卫生区参与埃博拉疫苗试验的经历。
Am J Trop Med Hyg. 2024 Jul 2;111(3):578-588. doi: 10.4269/ajtmh.23-0581. Print 2024 Sep 4.
2
The potential risk components and prevention measures of the Ebola virus disease outbreak in Liberia: An in-depth interview with the health workers and stakeholders.利比里亚埃博拉病毒病暴发的潜在风险因素及预防措施：对卫生工作者和利益相关者的深入访谈
Belitung Nurs J. 2024 Feb 28;10(1):67-77. doi: 10.33546/bnj.3069. eCollection 2024.
3
Modeling Supply and Demand Dynamics of Vaccines against Epidemic-Prone Pathogens: Case Study of Ebola Virus Disease.针对易引发流行疾病原体的疫苗供需动态建模：埃博拉病毒病案例研究
Vaccines (Basel). 2023 Dec 25;12(1):24. doi: 10.3390/vaccines12010024.
4
Evolving Horizons: Adenovirus Vectors' Timeless Influence on Cancer, Gene Therapy and Vaccines.不断演变的视野：腺病毒载体对癌症、基因治疗和疫苗的永恒影响。
Viruses. 2023 Dec 3;15(12):2378. doi: 10.3390/v15122378.
5
Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges.埃博拉病毒病疫苗：研发、当前观点与挑战
Vaccines (Basel). 2023 Jan 26;11(2):268. doi: 10.3390/vaccines11020268.
6
Model-based evaluation of the impact of prophylactic vaccination applied to Ebola epidemics in Sierra Leone and Democratic Republic of Congo.基于模型的评估：在塞拉利昂和刚果民主共和国实施埃博拉疫情预防接种的影响。
BMC Infect Dis. 2022 Oct 4;22(1):769. doi: 10.1186/s12879-022-07723-6.
7
Prevalence of malaria and helminth infections in rural communities in northern Sierra Leone, a baseline study to inform Ebola vaccine study protocols.塞拉利昂北部农村社区疟疾和寄生虫感染的流行情况，为埃博拉疫苗研究方案提供基线研究信息。
PLoS One. 2022 Jul 6;17(7):e0270968. doi: 10.1371/journal.pone.0270968. eCollection 2022.
8
Risk factors for Ebola virus disease among household care providers, Sierra Leone, 2015.2015 年塞拉利昂家庭护理人员中埃博拉病毒病的风险因素。
Int J Epidemiol. 2022 Oct 13;51(5):1457-1468. doi: 10.1093/ije/dyac081.
9
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.两剂异源 Ad26.ZEBOV、MVA-BN-Filo 埃博拉疫苗在健康和 HIV 感染者中的安全性和免疫原性：在非洲进行的一项随机、安慰剂对照的 II 期临床试验。
PLoS Med. 2021 Oct 29;18(10):e1003813. doi: 10.1371/journal.pmed.1003813. eCollection 2021 Oct.
10
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.在塞拉利昂成年人中，两剂腺病毒载体 26 型（Ad26.ZEBOV）和 MVA-BN-Filo 埃博拉疫苗接种方案的安全性和长期免疫原性：一项联合开放标签、非随机 1 期和随机、双盲、对照 2 期试验。
Lancet Infect Dis. 2022 Jan;22(1):97-109. doi: 10.1016/S1473-3099(21)00125-0. Epub 2021 Sep 13.
本文引用的文献
1
The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV∆G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak.塞拉利昂引入埃博拉疫苗试验：在西非埃博拉疫情期间评估 rVSV∆G-ZEBOV-GP 疫苗的耐受性和安全性。
J Infect Dis. 2018 May 18;217(suppl_1):S6-S15. doi: 10.1093/infdis/jiy020.
2
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.单次接种 rVSV-ZEBOV 疫苗后抗埃博拉病毒病抗体持久性的跨剂量和跨洲决定因素：一项观察性队列研究。
Lancet Infect Dis. 2018 Jul;18(7):738-748. doi: 10.1016/S1473-3099(18)30165-8. Epub 2018 Apr 5.
3
Questionable efficacy of the rVSV-ZEBOV Ebola vaccine.重组水疱性口炎病毒载体埃博拉病毒疫苗（rVSV-ZEBOV）疗效存疑。
Lancet. 2018 Mar 17;391(10125):1021. doi: 10.1016/S0140-6736(18)30560-9. Epub 2018 Mar 15.
4
Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.在利比里亚进行的两种预防埃博拉疫苗的2期安慰剂对照试验。
N Engl J Med. 2017 Oct 12;377(15):1438-1447. doi: 10.1056/NEJMoa1614067.
5
Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV.系统疫苗学确定早期先天免疫特征作为埃博拉疫苗rVSV-ZEBOV抗体反应的一个相关指标。
Cell Rep. 2017 Aug 29;20(9):2251-2261. doi: 10.1016/j.celrep.2017.08.023.
6
Immunogenicity of Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine Expressing Glycoprotein from the 2014 Epidemic Strain in Mice.重组腺病毒 5 型载体埃博拉疫苗在小鼠中表达 2014 年流行株糖蛋白的免疫原性。
Hum Gene Ther. 2018 Jan;29(1):87-95. doi: 10.1089/hum.2017.018. Epub 2017 Dec 18.
7
Controversial Ebola vaccine trials in Ghana: a thematic analysis of critiques and rebuttals in digital news.加纳有争议的埃博拉疫苗试验：对数字新闻中批评与反驳的主题分析
BMC Public Health. 2017 Aug 7;17(1):642. doi: 10.1186/s12889-017-4618-8.
8
Open-label phase I clinical trial of Ad5-EBOV in Africans in China.在中国开展的针对非洲人的 Ad5-EBOV 开放性 I 期临床试验。
Hum Vaccin Immunother. 2017 Sep 2;13(9):2078-2085. doi: 10.1080/21645515.2017.1342021. Epub 2017 Jul 14.
9
Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.评估健康成年人中重组水疱性口炎病毒埃博拉疫苗的安全性和免疫原性：一项随机临床试验。
CMAJ. 2017 Jun 19;189(24):E819-E827. doi: 10.1503/cmaj.170074.
10
Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.rVSV∆G-ZEBOV-GP 埃博拉病毒疫苗候选物在健康成年人中的安全性和免疫原性：一项 1b 期随机、多中心、双盲、安慰剂对照、剂量反应研究。
Lancet Infect Dis. 2017 Aug;17(8):854-866. doi: 10.1016/S1473-3099(17)30313-4. Epub 2017 Jun 9.
Zotero 插件